International Consolidated Companies, Inc. (INCC.OB) is focused on the acquisition of healthcare, technology, and environmental companies. The company looks for other companies located within the Asian markets to extend country’s growing potential.
International Consolidated Companies has chosen to enter the bio-tech pharmaceuticals and bio-engineered medicines markets. The pharmaceutical market in China has managed to maintain steady growth with reported revenues of $54.6 billion in 2007. The company offers foreign companies a chance to get on the U.S markets.
The companies that International Consolidated considers for acquisition must meet specific criteria within their acquisition model. International Consolidated retains a percentage of each target company in order to develop a growth-oriented investment base. Recent acquisitions include China Gene, Ltd. (Hong Kong), along with its subsidiaries Shanghai Huaxin High Biotechnology and Sichuan Kelan Bio-Tech Pharmaceutical Company.
Let us hear your thoughts: International Consolidated Companies, Inc. Message Board